Author

Marie-Helene Blanchet Zumofen

Observed names: BlanchetZumofen, M.-H., M. Blanchet Zumofen, Marie-Hélène Blanchet Zumofen, Marie‐Helene Blanchet Zumofen, marie-helene blanchetzumofen

Institution: Roche (Switzerland)

Observed institution: Roche (Switzerland)

ORCID: 0000-0003-2760-2880

Observed ORCID: 0000-0003-2760-2880

OpenAlex ID: A5075595889

Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review

2022 · Marie-Hélène Blanchet Zumofen, Jeff Frimpter, et al. · PharmacoEconomics · 57

PDF

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

2021 · Arndt Vogel, Lorenza Rimassa, et al. · Liver Cancer · 54

PDF

Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis

2023 · Arndt Vogel, Richard S. Finn, et al. · Liver Cancer · 21

Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy

2023 · Sarah F. McGough, Natasha Shamas, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 13

Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma

2023 · Francesc Bosch, John Kuruvilla, et al. · Clinical Lymphoma Myeloma & Leukemia · 13

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium

2025 · Michael Boyiadzis, Andrew H. Wei, et al. · Cancer · 11

A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom

2024 · Svenn Alexander Kommandantvold, Annabelle Lemenuel-Diot, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 8

PDF

Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.

2020 · Arndt Vogel, Lorenza Rimassa, et al. · Journal of Clinical Oncology · 8

Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States

2024 · Svenn Alexander Kommandantvold, Shih-Chen Chang, et al. · Infectious Diseases and Therapy · 7

PDF

An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy

2022 · Sarah F. McGough, Natasha Shamas, et al. · Blood · 6

Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma

2023 · Javier Sanchez Alvarez, Mahmoud Jaber, et al. · Oncology and Therapy · 1

PDF

CO103 Evaluating EU-HTA PICO Exercise Outcomes: Duration of Response and Time to Response in Hepatocellular Carcinoma Using Randomization-Preserving Methods with IMbrave150 Data

2025 · Aino K. Launonen, Ali Jaffer, et al. · Value in Health

EE644 Reducing the Transmission and Annual Burden of Influenza in the UK With Baloxavir Marboxil: A Cost-Effectiveness Analysis Using Evidence From the CENTERSTONE Trial

2025 · Svenn Alexander Kommandantvold, Chris Skedgel, et al. · Value in Health

576 | Fixed‐duration Subcutaneous Mosunetuzumab Had Similar Efficacy but Lower Cytokine Release Syndrome Risk Versus Epcoritamab in 3l+ Follicular Lymphoma: an Indirect Comparison

2025 · N. Ghosh, M. Antoniou, et al. · Hematological Oncology

PDF

922. Cost-effectiveness of baloxavir marboxil versus oseltamivir or no treatment for the management of influenza in the United States

2023 · Svenn Hansen, Shih-Chen Cheng, et al. · Open Forum Infectious Diseases

PDF

Supplementary Material for: Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

2021 · Vogel, A., Rimassa, L., et al. · Figshare

Works count: 16

Citation count: 198

H-index: 8

I10-index: 6